In addition, a preclinical study revealed that PD-1 checkpoint inhibition combined with an adenoviral-based vaccine targeting HPV-E6/E7 protein in the context of E6+/E7+ tumor-bearing mice resulted in a more effective antitumor response (70). The gene discussed is PDCD1; the disease is neoplasm.